DelveInsight's "Cholangiocarcinoma Market Insights, Epidemiology, and Market Forecast 2030" reports deliver an in-depth understanding of the disease, historical and forecasted epidemiology, the pipeline insight as well as the Cholangiocarcinoma market size and shares analysis in the seven major markets (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. The report also covers emerging drugs, current treatment practices, Cholangiocarcinoma market shares of the individual therapies, a detailed current Cholangiocarcinoma treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the market.
Cholangiocarcinoma (CCA) also known as Biliary Tract Cancer is a rare and heterogeneous malignant neoplasm with epithelial cell origin of the biliary duct and histologic and biochemical features of cholangiocyte differentiation.
According to the ICD 10 classification of the disease, CCA is coded as intrahepatic bile duct carcinoma (C22.1), extrahepatic bile duct carcinoma (C24.0), Ampulla of Vater (C24.1), overlapping lesion of the biliary tract (C24.8) (includes malignant neoplasm of biliary tract whose point of origin cannot be classified to any one of the categories); or it involves both intrahepatic and extrahepatic bile ducts (C22.0-C24.1), and Biliary tract unspecified (C24.9).
Cholangiocarcinoma Market Key Facts
- Among the EU5 countries, Germany had the highest incident population of Cholangiocarcinoma (CCA), followed by Italy and the United Kingdom. In Italy, Cholangiocarcinoma incidence was recorded to be 3.36/100,000, and CCAs accounted approximately for 3% of total primitive liver cancers. (B. Maria et al.)
- DelveInsight analysis concluded that the incidence rate varied based on type-specific cases and the estimates showed an increasing trend in the Intrahepatic CCA cases, while Extrahepatic CCA showed a decreasing trend or in some cases are stable
- Among the stage-specific cases, 22.9 were localized, 36.9% were regional, and 40.2% belong to the distant stage of Cholangiocarcinoma in the US. [N Patel et al.]
- The Japanese population has relatively higher rates of Cholangiocarcinoma incidence (Hiroshima 3.05/100,000, Osaka 3.4/100,000) as compared to other Asian countries.
- According to DelveInsight’s analysis, Males are more prone to Cholangiocarcinoma than females
Cholangiocarcinoma Market Size
The Cholangiocarcinoma Market Size is expected to increase during the forecast period owing to the increasing Incident population of Cholangiocarcinoma (CCA) patients in the 7MM.
The Cholangiocarcinoma market analysis section of the report helps to understand the current and forecasted Cholangiocarcinoma market trends and growth by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers. The report gives complete detail of Cholangiocarcinoma Market Size and Shares of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Cholangiocarcinoma Therapeutics Market
Till now, surgical treatments are the only potentially curative therapeutic options for all the subtypes of CCA. However, the majority of CCA patients are diagnosed with late-stage disease, and nearly more than one-fourth of patients considered resectable are found to be unresectable during explorative laparotomy. In the coming years, the improvements in the molecular understanding of Cholangiocarcinoma through whole-genome analysis may identify multiple actionable mutations, leading to the development of targeted agents with promising results in early clinical trials
Cholangiocarcinoma Epidemiology Forecast
The Cholangiocarcinoma epidemiology section covers insights about historical and current Cholangiocarcinoma patient pool and forecasted trends for every seven major countries (i.e., the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan. It helps to recognize the causes of current and forecasted Cholangiocarcinoma Epidemiology trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends, along with assumptions undertaken.
Cholangiocarcinoma Epidemiology Segmentation
- Diagnosed incident cases of Cholangiocarcinoma
- Gender-Specific Diagnosed Incident Cases of Cholangiocarcinoma
- Biomarker-Specific Diagnosed Incident Cases of
- Biomarker-Specific Diagnosed Incident Cases of ECCA
- Type-Specific Diagnosed Incident cases of Cholangiocarcinoma
- Stage-Specific Diagnosed Incident Cases of Intrahepatic CCA
- Stage-Specific Diagnosed Incident Cases of Extrahepatic CCA
- Age-Specific Diagnosed Incident Cases of CCA
With numerous efforts, the market is hoping to be fuelled by providing better and long-term treatment options for Cholangiocarcinoma that are expected to enter the market by 2030.
Cholangiocarcinoma Companies:
Some of the key companies in the Cholangiocarcinoma Market includes Nucana, Bayer, Agios Pharmaceuticals, Incyte Corporation, QED Therapeutics, Delcath Systems, Loxo Oncology, Hoffmann-La Roche, Basilea Pharmaceutica, Janssen Research & Development, Merck Sharp & Dohme Corp, and many others. Cholangiocarcinoma Therapies covered in the report include Infigratinib, Pemigatinib, Ivosidenib, Melphalan, Hydrochloride, Acelarin, Regorafenib, Larotrectinib, Entrectinib, Derazantinib, Erdafitinib, Keytruda, and others.
For more details, visit: Cholangiocarcinoma Market Size